Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 5/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5379951 | 0.71 | — | — | |
| SCHEMBL18237727 | 0.63 | HSD17B10 (0.42) | — | |
| Trifluoroacetic Acid SCHEMBL5379943 | 0.61 | HRH4 (0.44) | — | |
| SCHEMBL3424225 | 0.60 | SLC7A5 (0.39) | — | |
| SCHEMBL28393898 | 0.57 | CETP (0.32) | — | |
| Trifluoroacetic Acid SCHEMBL30870503 | 0.56 | L3MBTL1 (0.31) | — | |
| SCHEMBL906263 | 0.56 | FAAH (0.30) | — | |
| SCHEMBL13911135 | 0.55 | SMN1; SMN2 (0.39) | — | |
| SCHEMBL28245268 | 0.55 | GABRR1 (0.31) | — | |
| SCHEMBL15935288 | 0.55 | L3MBTL1 (0.36) | SCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213362-A1 | 2-NH-HETEROARYLIMIDAZOLES WITH ANTIBACTERIAL ACTIVITY | REPLIDYNE, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-7220757-B2 | Compositions and methods for topical administration of 2-NH-heteroarylimidazoles | REPLIDYNE, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060014748-A1 | 2-NH-heteroarylimidazoles with antibacterial activity | BERGE JOHN | 2006-01-19 | — | — | US | disclosed |
| US-6943175-B2 | 2-NH-heteroarylimidazoles with antibacterial activity | REPLIDYNE, INC. (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040147548-A1 | 2-NH-heteroarylimidazoles with antibacterial activity | REPLIDYNE, INC. | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147548-A1 | 2-NH-heteroarylimidazoles with antibacterial activity | NSUN3, TRMT1, NOP2 | S1PR4 4801/4885S1PR1 4648/4885S1PR5 4646/4885 |
| US-20070213362-A1 | 2-NH-HETEROARYLIMIDAZOLES WITH ANTIBACTERIAL ACTIVITY | MET, ASNS, MRPS22 | S1PR4 3105/4885S1PR1 1682/4885S1PR5 2035/4885 |
| US-20060014748-A1 | 2-NH-heteroarylimidazoles with antibacterial activity | TRMT1, NSUN3, NOP2 | S1PR4 4803/4885S1PR1 4697/4885S1PR5 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.